Genetic manipulation of Escherichia coli central carbon metabolism for efficient production of fumaric acid.

08:00 EDT 9th August 2018 | BioPortfolio

Summary of "Genetic manipulation of Escherichia coli central carbon metabolism for efficient production of fumaric acid."

Fumaric acid is one of the top 12-biomass building-block chemicals. In this study, we reported manipulation of E. coli central carbon metabolism with the aim to decrease the by-products and improve fumaric acid production. PEP-dependent glucose phosphotransferase system was replaced with a galactose translocation system to minimize the consumption of phosphoenolpyruvate. Engineering anaplerotic pathway (phosphoenolpyruvate carboxylase) was employed to redistribute carbon flux from glycolysis to Krebs cycle. Deletion of malate dehydrogenase and overexpression of acetyl-CoA synthase could decrease the byproducts malic acid and acetic acid. The combined strategies led to fumaric acid yield up to 1.53 g/g dry cell weight, a 50% increase compared with the parental strain. The result demonstrated that these genetic modifications were effective strategies for improving the production of fumaric acid and the engineered strain may serve a platform microbial cell factory for efficient production of fumaric acid or other dicarboxylic acids.


Journal Details

This article was published in the following journal.

Name: Bioresource technology
ISSN: 1873-2976
Pages: 96-102


DeepDyve research library

PubMed Articles [22850 Associated PubMed Articles listed on BioPortfolio]

An enormous potential for niche construction through bacterial cross-feeding in a homogeneous environment.

Microorganisms modify their environment by excreting by-products of metabolism, which can create new ecological niches that can help microbial populations diversify. A striking example comes from expe...

In vivo assimilation of one-carbon via a synthetic reductive glycine pathway in Escherichia coli.

Assimilation of one-carbon compounds presents a key biochemical challenge, which limits their use as sustainable feedstocks for microbial growth and production. The reductive glycine pathway is a synt...

The ATP-stimulated translocation promoter (ASTP) activity of glycerol kinase plays central role in adipogenesis.

Glycerol kinase (GK) is a multifunctional enzyme located at the interface of carbohydrate and fat metabolism. It contributes to both central carbon metabolism and adipogenesis; specifically, through i...

DcuA of aerobically grown Escherichia coli serves as a nitrogen shuttle (L-aspartate/fumarate) for nitrogen uptake.

DcuA of Escherichia coli is known as an alternative C -dicarboxylate transporter for the main anaerobic C -dicarboxylate transporter DcuB. Since dcuA is expressed constitutively under aerobic and anae...

Iterative Genome Editing of Escherichia coli for 3-Hydroxypropionic Acid Production.

Synthetic biology requires strategies for the targeted, efficient, and combinatorial engineering of biological sub-systems at the molecular level. Here, we report the use of the iterative CRISPR EnAbl...

Clinical Trials [7093 Associated Clinical Trials listed on BioPortfolio]

Enteropathogenic Escherichia Coli (EPEC): Does it Have a Role in Colorectal Tumourigenesis?

Despite the characterization of many aetiologic genetic changes. The specific causative factors in the development of sporadic colorectal cancer remain unclear. This study was performed to...

Epidemiology of ST131 in Besançon University Hospital

The sequence type 131 (ST131) is a predominant lineage among extraintestinal pathogenic Escherichia coli. It plays a major role in the worldwide dissemination of E. coli that produce exten...

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)

This study is to evaluate lot-lot consistency of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin®.

Characteristics of Lower Respiratory Tract Escherichia Coli Isolates in Mechanically Ventilated Intensive Care Patients

Prospective, multicenter observational study to collect Escherichia coli (E. coli) isolates originating from mechanically ventilated intensive care unit (ICU) patients; in order to charact...

The Protective Immune Response to Attenuated Enterotoxigenic Escherichia Coli Infection

The existing diarrhoeagenic Escherichia coli (E. coli) challenge model is already suitable for dietary interventions in its current form, targeted to impact on the immediate clinical sympt...

Medical and Biotech [MESH] Definitions

Strains of ESCHERICHIA COLI that are a subgroup of SHIGA-TOXIGENIC ESCHERICHIA COLI. They cause non-bloody and bloody DIARRHEA; HEMOLYTIC UREMIC SYNDROME; and hemorrhagic COLITIS. An important member of this subgroup is ESCHERICHIA COLI O157-H7.

A species of gram-negative, rod-shaped bacteria belonging to the K serogroup of ESCHERICHIA COLI. It lives as a harmless inhabitant of the human LARGE INTESTINE and is widely used in medical and GENETIC RESEARCH.

Strains of Escherichia coli that possess virulence traits which allow them to invade, colonize, and induce disease in tissues outside of the GASTROINTESTINAL TRACT. They are a cause of URINARY TRACT INFECTIONS (UROPATHOGENIC ESCHERICHIA COLI); neonatal MENINGITIS; SEPSIS; PNEUMONIA; and SURGICAL WOUND INFECTION.

An enterohemorrhagic Escherichia coli of the O subfamily that can cause severe FOODBORNE DISEASE. The H4 serotype strain produces SHIGA TOXINS and has been linked to human disease outbreaks, including some cases of HEMOLYTIC-UREMIC SYNDROME, resulting from contamination of foods by feces containing E. coli O104.

A verocytotoxin-producing serogroup belonging to the O subfamily of Escherichia coli which has been shown to cause severe food-borne disease. A strain from this serogroup, serotype H7, which produces SHIGA TOXINS, has been linked to human disease outbreaks resulting from contamination of foods by E. coli O157 from bovine origin.

Quick Search


DeepDyve research library

Searches Linking to this Article